We sought to prospectively compare the prognostic value of cardiac iodine-123 (I-123) metaiodobenzylguanidine (MIBG) imaging with peak oxygen comsumption (VO2) and plasma BNP level in patients with advanced heart failure (AHF) waiting for heart transplant.
Results: Early and late cardiac MIBG uptake were correlated with ejection fraction (r=0.33 and r=0.42). With a median follow up of 494 days, NYHA (p=0.03), plasma BNP (p=0.002), peak VO2 (p=0.03) were predictive of death or heart transplantation, but only plasma BNP emerged by multivariate analysis. WOR>36.63% (1 st quartile) was predictive on kaplanMeier analysis.
Conclusions:
In AHF patients, VO2 and BNP plasma level are stronger prognosticator than MIBG imaging related parameters. MIBG should be reserved to patients with mild to moderate heart failure while BNP remains the most powerful prognostic index whatever the severity of heart failure.
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Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording Fabien Despas (1), Charlotte Trouillet (2), Nicolas Franchitto (1), Michel Galinier (2), Jean-Michel Senard (1), Atul Pathak (1) (1) Inserm U858, Toulouse, CHU Toulouse, Cardiologie, Toulouse, France Background: Levosimendan is a new inodilatory agent with calcium sensitizing activity. A major concern regarding the use of inotropic agent in heart failure is their effect on the sympathetic tone. This effect could explain increase in short term mortality with other inotropes. In this setting, the aim of our study was to assess the effect of levosimendan on sympathetic tone measured directly by microneurography.
Methods:
In a group of acute decompensated heart failure patients, we assessed cardiac performance by digital plethysmography (Finometer©) measurement. Sympathetic tone was assessed through recording of muscle sympathetic nerve activity by microneurography. Recording were done blindy, for each patient after dobutamine perfusion was stopped (baseline) and 48 hours after levosimendan infusion. Clinical, biological and morphological data were collected. We compared cardiac parameters and sympathetic nerve activity before and after administration of levosimedan.
Results: 13 patients with refractory chronic heart failure were recruited (aged 48±3.6 years). Systolic blood pressure and rate pressure product (mmHg x Beat/min) decreased significantly after levosimendan infusion (p<0.05). Cardiac output and stroke volume assessed by Finometer were significantly increased after levosimendan infusion (p<0.05). A significant decrease of muscle sympathetic nerve activity is observed after levosimendan infusion (p<0.01). Levosimendan cause a significant reduction of plasma brain natriuretic preptide (BNP) after the initiation of the drug (p<0.01).
Conclusion:
Levosimendan induced improvement of cardiac performance is associated with a decreased in MSNA. This study show for the first time that levosimendan has no direct detrimental effect on the sympathetic nervous system.
Significance of increased plasma BNP level in Patients with Hypertrophic Cardiomyopathy
Olivier Gournay, Richard Isnard, Philippe Charron, Michel Komajda Groupe hospitalier Pitié Salpêtrière, Cardiologie, Paris, France Background: Plasma BNP is widely used in the management of patients with systolic heart failure; however it has been less studied in patients with hypertrophic cardiomyopathy. We hypothetized that increased plasma BNP level could be associated with heart failure symptoms and increased left ventricle filling pressure in patients with HCM.
Methods:
We studied 62 consecutive patients with HCM admitted for evaluation in our outpatient clinic. In all patients, clinical examination, complete echocardiography and plasma BNP and creatinine measurements were performed.
Results:
The mean BNP value was 297 ± 282 pg/mL. In univariate analysis, BNP showed a significant relationship to age (R_ = 0,1862; p = 5.10-4), magnitude of dyspnea, expressed by New York Heart Association (NYHA) functional class: I, 114 ± 114 pg/mL; II, 224 ± 168 pg/mL; III, 523 ± 280 pg/mL; IV, 816 ± 368 pg/mL (p < 10-4), atrial fibrillation (p < 0,009) and creatinine clearance (R_ = 0,2328; p < 10-4). BNP levels were also correlated with lateral annular Ea velocity (R_ = 0,2148; p = 10-4), increased LV filling pressure defined as E/A > 2 or E/Ea > 10 (R_ = 0,376; p < 10-4), left atrial size (R_ = 0,1686; p = 9.10-4), systolic pulmonary arterial pressure (R_ = 0,2299; p < 10-4). There was no relation between BNP and LV outflow tract gradient at rest or maximal LV wall thickness. Variables with significant multivariable relation with BNP were NYHA functional class, mitral lateral Ea velocity, increased LV filling pressure, and creatinine clearance.
Conclusion:
BNP levels in patients with HCM are related to the presence and magnitude of heart failure symptoms and LV filling pressure. Its prognostic value should be evaluated in these patients.
